Apple Taps Seasoned Executive To Head 'Secret' Team Developing Glucose Monitoring Device - Stocks To Watch
Portfolio Pulse from Vandana Singh
Apple Inc has appointed Tim Millet to oversee its team developing a noninvasive blood sugar monitor. The move signals a significant step in Apple's health technology endeavors. High-tech diabetes stocks DexCom Inc, Insulet Corporation, and Tandem Diabetes Care Inc are down YTD. Abbott Laboratories is also a player in the market. Apple aims to make the glucose monitor compact enough to fit within the Apple Watch.
September 15, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apple's appointment of Tim Millet to oversee the development of a noninvasive blood sugar monitor could boost its position in the health tech market.
Apple's move to develop a noninvasive blood sugar monitor under the leadership of Tim Millet could potentially open a new revenue stream for the company and strengthen its position in the health tech market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Abbott Laboratories is also a player in the noninvasive blood sugar monitor market, which could face increased competition from Apple.
As Apple moves into the noninvasive blood sugar monitor market, existing players like Abbott Laboratories could face increased competition.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
DexCom's stock is down YTD, which could be influenced by Apple's move into the noninvasive blood sugar monitor market.
DexCom's stock performance could be negatively impacted by Apple's move into the noninvasive blood sugar monitor market, adding to the competition.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
Insulet Corporation's stock is down YTD, which could be influenced by Apple's move into the noninvasive blood sugar monitor market.
Insulet Corporation's stock performance could be negatively impacted by Apple's move into the noninvasive blood sugar monitor market, adding to the competition.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
Tandem Diabetes Care Inc's stock is down YTD, which could be influenced by Apple's move into the noninvasive blood sugar monitor market.
Tandem Diabetes Care Inc's stock performance could be negatively impacted by Apple's move into the noninvasive blood sugar monitor market, adding to the competition.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50